Historical Background

Upon request by the Government of Uganda , Cipla Ltd, one of the world’s leading pharmaceutical manufacturers, agreed to extend technical assistance to Uganda through a joint venture with a local partner Quality Chemicals Ltd (QCL), a leading life sciences and distribution company in the country, to enable Uganda locally manufacture antiretroviral drugs to combat HIV/AIDS and anti-malarial drugs under licence from Cipla Ltd.

The Partnership between QCL and CIPLA led to the formation of Quality Chemical Industries Limited (QCIL) which was formerly incorporated on June 10th 2005. QCIL has since then acquired two additional investors and partners, namely Capitalworks International Partnership Fund and TLG Capital Fund. These new partners bring on board a wealth of experience as well as additional financing to bolster QCIL’s operations.

  • Concept

This project is borne of the cognizance that India, the biggest source of pharmaceuticals for Africa in general and anti-HIV/AIDS and anti-malarial products in particular will cease to be a reliable source of relevant, good quality and affordable pharmaceuticals because it has ratified the Trade-Related Aspects of Intellectual Property Rights (TRIPS) accord under the World Trade Organization which will bar it from continuing to provide Uganda with affordable medicines.

The implications of the TRIPS agreement potentially have devastating consequences to the people of Uganda and the rest of Africa in their effort to contain these killer diseases as the relevant essential medicines will no longer be affordable as the population will have to rely on branded medicines which are significantly more expensive than the generic medicines from Asia.


Africa needs low cost, efficacious, safe and relevant pharmaceuticals. Africa needs to be less reliant on other countries for its critical needs like medicines. HIV/AIDS and Malaria are predominantly an African problem. Africa is home to 60% of the world’s HIV/AIDS sufferers and 80% of all global Malaria sufferers and yet our economies do not reflect this.

By being net importers of products that are addressing problems that are predominantly African, means that we are spending a lot of money with no benefit to our people. Local manufacturing will address this contradiction and thus provide an African solution to an African problem.

Press Release

Coopers U Ltd

QCIL 2011 All rights Reserved | Declaimer